The study did not achieve statistical significance on either of its primary endpoints – cognition and activities of daily living.
Peter Meldrum, president and CEO of Myriad Genetics, said: “We are disappointed that Flurizan failed to achieve significance in this study, and we will now discontinue development of this compound. The discontinuation of Flurizan will reduce our pharmaceutical development spend substantially and should enable Myriad to achieve profitability next year, ending June 30, 2009.”